Skip to Content

Imfinzi Approval History

Imfinzi (durvalumab) is an anti-PD-L1 (programmed death ligand-1) human monoclonal antibody for the treatment of patients with metastatic urothelial carcinoma and for the treatment of patients with unresectable non-small cell lung cancer that has not progressed after chemoradiation.

Development History and FDA Approval Process for Imfinzi

Feb 16, 2018Approval FDA Approves Imfinzi (durvalumab) for Unresectable Stage III Non-Small Cell Lung Cancer
May  1, 2017Approval AstraZeneca’s Imfinzi (durvalumab) Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer
Dec  9, 2016US FDA Accepts First Biologics License Application for AstraZeneca’s Durvalumab in Bladder Cancer
Feb 17, 2016Durvalumab Granted Breakthrough Therapy Designation by U.S. FDA for Treatment of Patients with PD-L1 Positive Urothelial Bladder Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.